A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 16,978 shares of TBPH stock, worth $160,781. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,978
Previous 16,978 -0.0%
Holding current value
$160,781
Previous $136,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$7.66 - $10.25 $29,314 - $39,226
3,827 Added 29.1%
16,978 $136,000
Q2 2024

Jul 29, 2024

SELL
$8.29 - $9.92 $58 - $69
-7 Reduced 0.05%
13,151 $111,000
Q1 2024

Apr 25, 2024

BUY
$8.22 - $11.59 $31,466 - $44,366
3,828 Added 41.03%
13,158 $118,000
Q4 2023

Jan 30, 2024

BUY
$8.58 - $11.4 $19,107 - $25,387
2,227 Added 31.35%
9,330 $104,000
Q3 2023

Oct 25, 2023

SELL
$8.38 - $10.44 $3,829 - $4,771
-457 Reduced 6.04%
7,103 $61,000
Q2 2023

Aug 07, 2023

SELL
$10.16 - $11.92 $3,982 - $4,672
-392 Reduced 4.93%
7,560 $78,000
Q1 2023

May 08, 2023

BUY
$9.87 - $11.44 $829 - $960
84 Added 1.07%
7,952 $86,000
Q4 2022

Feb 01, 2023

SELL
$9.65 - $11.34 $3,975 - $4,672
-412 Reduced 4.98%
7,868 $88,000
Q2 2022

Aug 09, 2022

SELL
$8.41 - $10.34 $2,253 - $2,771
-268 Reduced 3.14%
8,280 $75,000
Q1 2022

Apr 21, 2022

BUY
$8.33 - $12.96 $23,573 - $36,676
2,830 Added 49.49%
8,548 $82,000
Q3 2020

Nov 06, 2020

BUY
$14.79 - $22.49 $32,878 - $49,995
2,223 Added 63.61%
5,718 $85,000
Q1 2020

May 06, 2020

BUY
$17.84 - $31.21 $14,557 - $25,467
816 Added 30.46%
3,495 $81,000
Q4 2017

Jan 31, 2018

BUY
$25.82 - $35.66 $26,362 - $36,408
1,021 Added 61.58%
2,679 $75,000
Q3 2017

Nov 08, 2017

BUY
$23.88 - $34.96 $39,593 - $57,963
1,658
1,658 $57,000

Others Institutions Holding TBPH

About Theravance Biopharma, Inc.


  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $632M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track Zurcher Kantonalbank (Zurich Cantonalbank) Portfolio

Follow Zurcher Kantonalbank (Zurich Cantonalbank) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.